---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-024675"
form_type: "8-K"
ticker: "COGT"
cik: "0001622229"
company_name: "Cogent Biosciences, Inc."
filed_at: "2022-11-14T23:59:59+00:00"
generated_at: "2026-06-21T20:24:38.617349+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Cogent Biosciences Q3 net loss $35.1M; cash $289.1M, runway into 2025; Phase 3 PEAK trial started

## Summary
- Net loss $35.1M vs $19.1M YoY; R&D expense $29.9M (up from $14.8M) due to trials and team expansion.
- Cash & securities $289.1M as of Sep 30, 2022; cash runway expected into 2025.
- Phase 3 PEAK trial of bezuclastinib + sunitinib in second-line GIST patients initiated.
- Optimized bezuclastinib formulation shows >40% exposure improvement; potential patent protection to 2043.
- G&A expense $6.9M vs $5.0M YoY; non-cash stock comp included.

## SEC filing metadata
- accession: 0000950170-22-024675
- form_type: 8-K
- ticker: COGT
- cik: 0001622229
- company_name: Cogent Biosciences, Inc.
- filed_at: 2022-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1622229/000095017022024675/0000950170-22-024675-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1622229/000095017022024675/cogt-20221114.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-024675
- JSON: https://secwatch.observer/filing/0000950170-22-024675.json
- Plain text: https://secwatch.observer/filing/0000950170-22-024675.txt

## Key facts
- Earnings Releases
  Cogent Biosciences, Inc. reported the quarter ended September 30, 2022 results: net income $35.1 million.
  - Period: the quarter ended September 30, 2022
  - Net income: $35.1 million
  - Result: reported results
  source text: Net Loss: Net loss was $35.1 million for the th
  evidence_url: https://www.sec.gov/Archives/edgar/data/1622229/000095017022024675/0000950170-22-024675-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.